Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

PLYMOUTH MEETING, Pa., June 15, 2021 /PRNewswire/ -- Braeburn announces that today the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release injection for subcutaneous (SC) use (CIII ...

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder OUD is a complex and potentially ...

Credit: Braeburn. Brixadi is supplied as prefilled single-dose syringes in weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) doses. The Food and Drug Administration (FDA) has approved ...

Brixadi is the first treatment for opioid use disorder in the US with both weekly and monthly dosing Three million people in the US diagnosed with opioid use disorder LUND, Sweden, May 24, 2023 ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how ...

pharmacy solutions, announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...